热门出版物 - 学术资源搜索

h5 指数:61
h5 中位数:83

h5 指数是指在过去整整 5 年中所发表文章的 h 指数。h 指在 2019-2023 年间发表的 h 篇文章每篇至少都被引用过 h 次的最大值。隐藏

出版物的 h5 中位数，是指出版物的 h5 指数所涵盖的所有文章获得的引用次数的中位值。隐藏

#4 Pain & Pain Management

标题/作者	引用次数	年份
ARISE: A Phase 3 randomized trial of erenumab for episodic migraine DW Dodick, M Ashina, JL Brandes, D Kudrow, M Lanteri-Minet, V Osipova, ... Cephalalgia 38 (6), 1026-1037	481	2018
Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial V Skljarevski, M Matharu, BA Millen, MH Ossipov, BK Kim, JY Yang Cephalalgia 38 (8), 1442-1454	470	2018
Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1) M Ashina, J Saper, R Cady, BA Schaeffler, DM Biondi, J Hirman, ... Cephalalgia 40 (3), 241-254	256	2020
Guidelines of the International Headache Society for controlled trials of preventive treatment of chronic migraine in adults C Tassorelli, HC Diener, DW Dodick, SD Silberstein, RB Lipton, M Ashina, ... Cephalalgia 38 (5), 815-832	251	2018
Non-invasive vagus nerve stimulation for the acute treatment of episodic and chronic cluster headache: A randomized, double-blind, sham-controlled ACT2 study PJ Goadsby, IF de Coo, N Silver, A Tyagi, F Ahmed, C Gaul, RH Jensen, ... Cephalalgia 38 (5), 959-969	194	2018
Headache: A striking prodromal and persistent symptom, predictive of COVID-19 clinical evolution E Caronna, A Ballvé, A Llauradó, VJ Gallardo, DM Ariton, S Lallana, ... Cephalalgia 40 (13), 1410-1421	182	2020
Perceived triggers of primary headache disorders: A meta-analysis ABW Pellegrino, RE Davis-Martin, TT Houle, DP Turner, TA Smitherman Cephalalgia 38 (6), 1188-1198	166	2018
Guidelines of the International Headache Society for controlled trials of acute treatment of migraine attacks in adults HC Diener, C Tassorelli, DW Dodick, SD Silberstein, RB Lipton, M Ashina, ... Cephalalgia 39 (6), 687-710	165	2019
Acute migraine therapy with external trigeminal neurostimulation (ACME): A randomized controlled trial DE Chou, M Shnayderman Yugrakh, D Winegarner, V Rowe, D Kuruvilla, ... Cephalalgia 39 (1), 3-14	144	2019
A multicenter, prospective, single arm, open label, observational study of sTMS for migraine prevention (ESPOUSE Study) AJ Starling, SJ Tepper, MJ Marmura, EA Shamim, MS Robbins, ... Cephalalgia 38 (6), 1038-1048	137	2018
CGRP ligand and receptor monoclonal antibodies for migraine prevention: Evidence review and clinical implications DW Dodick Cephalalgia 39 (3), 445-458	131	2019
Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study M Ashina, S Tepper, JL Brandes, U Reuter, G Boudreau, D Dolezil, ... Cephalalgia 38 (10), 1611-1621	128	2018
Eptinezumab for prevention of chronic migraine: A randomized phase 2b clinical trial DW Dodick, RB Lipton, S Silberstein, PJ Goadsby, D Biondi, J Hirman, ... Cephalalgia 39 (9), 1075-1085	121	2019
Musculoskeletal dysfunction in migraine patients K Luedtke, W Starke, A May Cephalalgia 38 (5), 865-875	108	2018
The effects of aerobic exercise for persons with migraine and co-existing tension-type headache and neck pain. A randomized, controlled, clinical trial LS Krøll, CS Hammarlund, M Linde, G Gard, RH Jensen Cephalalgia 38 (12), 1805-1816	105	2018
Vestibular migraine: An update on current understanding and future directions TC Huang, SJ Wang, A Kheradmand Cephalalgia 40 (1), 107-121	104	2020
Current understanding of trigeminal ganglion structure and function in headache K Messlinger, AF Russo Cephalalgia 39 (13), 1661-1674	100	2019
Headache associated with COVID-19: Frequency, characteristics and association with anosmia and ageusia PA Sampaio Rocha-Filho, JE Magalhães Cephalalgia 40 (13), 1443-1451	97	2020
Guidelines of the International Headache Society for controlled trials of preventive treatment of migraine attacks in episodic migraine in adults HC Diener, C Tassorelli, DW Dodick, SD Silberstein, RB Lipton, M Ashina, ... Cephalalgia 40 (10), 1026-1044	95	2020
Long-term safety and tolerability of erenumab: Three-plus year results from a five-year open-label extension study in episodic migraine M Ashina, PJ Goadsby, U Reuter, S Silberstein, D Dodick, GA Rippon, ... Cephalalgia 39 (11), 1455-1464	95	2019

1 - 20

计算机程序会自动估算并确定日期和引用次数。